Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Arance

Showing results (91-100 of 92) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 92 results.
Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
Pageof 10

Showing results (91-100 of 92) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 92 results.
Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
Pageof 10